Loading
The first registered STI-3258 TROP-2 study was withdrawn before enrolling any participants.
NCT05060276 describes an anti-TROP2 antibody-drug conjugate phase 1 study, withdrawn with zero actual participants because the protocol changed to phase 2. Withdrawal of this study is not evidence of clinical inefficacy or proof that the entire asset was abandoned.
Anti-TROP2 antibody-drug conjugate described in NCT05060276. Connects to TROP2.
1.STI-3258's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"STI-3258" OR ABSTRACT:"STI-3258") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STI-3258, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/